Welcome to our dedicated page for Corvus Pharmaceu SEC filings (Ticker: CRVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) SEC filings page on Stock Titan provides access to the company’s public reports as filed with the U.S. Securities and Exchange Commission. Corvus is a Delaware-incorporated, clinical-stage biopharmaceutical company whose common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the Nasdaq Global Market. Its filings give structured detail on operations, risk factors, capital structure and governance as it advances immunotherapy programs for cancer and immune diseases.
Through this page, you can review current and periodic reports such as Forms 8-K, which Corvus uses to announce material events including financial results, business updates and board of director changes. For example, recent 8-K filings have furnished press releases on quarterly financial results and described the appointment of a new director to the Board and its committees.
Investors researching CRVS can also use this section to locate annual reports (Form 10-K) and quarterly reports (Form 10-Q), where available, which typically discuss the company’s clinical-stage pipeline, including the ITK inhibitor soquelitinib, the adenosine A2a receptor inhibitor ciforadenant and the anti-CD73 antibody mupadolimab. These filings often outline key clinical programs such as the registration Phase 3 trial in relapsed/refractory peripheral T cell lymphoma and trials in atopic dermatitis and Autoimmune Lymphoproliferative Syndrome.
Stock Titan enhances these documents with AI-powered summaries that highlight important sections, helping readers quickly identify information on clinical development, collaborations, equity structure and risk disclosures without reading every page. Real-time updates from EDGAR mean new CRVS filings, including any future Forms 4 related to insider transactions or proxy statements on executive and director compensation, can be reviewed promptly from a single, organized interface.
The Vanguard Group filed Amendment No. 1 to a Schedule 13G for Corvus Pharmaceuticals Inc, reporting 0 shares beneficially owned of Common Stock and 0% ownership as stated in the amendment dated 03/13/2026. The filing states Vanguard reorganized internally on January 12, 2026, and certain subsidiaries now report ownership separately in reliance on SEC Release No. 34-39538.
The signature block shows the filing was signed by Ashley Grim, Head of Global Fund Administration, on 03/26/2026.
Corvus Pharmaceuticals, Inc. established an amended at-the-market equity program to sell up to $200,000,000 of common stock through Jefferies LLC as sales agent under a newly filed automatic shelf registration on Form S-3.
The new Amended and Restated Open Market Sale Agreement replaces a prior $100,000,000 arrangement under which no shares had been sold as of March 13, 2026. Jefferies will use commercially reasonable efforts to place shares by various permitted methods and may earn a commission of up to 3.0% of the gross sales price per share.
Registers up to $200,000,000 of common stock for sale in an amended at-the-market program. Corvus Pharmaceuticals amended its open market sales agreement with Jefferies to increase the maximum aggregate offering price from $100,000,000 to $200,000,000, with Jefferies serving as sales agent. The company has not sold shares under the prior agreement and suspended the prior program effective January 20, 2026. Sales, if any, will be made from time to time on the Nasdaq Global Market under an at the market plan; Jefferies may receive up to 3.0% of gross proceeds as compensation. The prospectus cites a March 11, 2026 last reported sale price of $16.90 and states shares outstanding of 74,696,629 as of December 31, 2025.
Corvus Pharmaceuticals, Inc. has filed a Form S-3 shelf registration to allow the company to offer from time to time common stock, preferred stock, debt securities, warrants and units under a single shelf prospectus. The shelf permits multiple offerings after the registration statement is effective.
The prospectus notes the company’s common stock trades on Nasdaq under the symbol CRVS and cites a March 11, 2026 last reported sale price of $16.90 per share. The prospectus also discloses capital structure details (authorized common and preferred shares) and that, as of December 31, 2025, Pre-Funded Warrants to purchase up to 8,275,913 shares were outstanding.
Corvus Pharmaceuticals files its Annual Report describing a late-stage immunology and oncology pipeline built around T‑cell modulation. The lead drug, soquelitinib, is in a registrational Phase 3 trial for relapsed peripheral T‑cell lymphoma and a Phase 2 trial for moderate‑to‑severe atopic dermatitis.
Earlier Phase 1 work in atopic dermatitis showed meaningful EASI score reductions versus placebo and favorable safety. Corvus is also advancing ciforadenant in kidney cancer and mupadolimab for future oncology and infectious disease uses, supported by a broad global patent estate.
As of June 30, 2025, non‑affiliate common stock market value was about $251.9 million, and as of March 12, 2026, 83,992,407 common shares were outstanding.
Corvus Pharmaceuticals provided a business update and reported fourth quarter and full year 2025 results, emphasizing progress for its lead ITK inhibitor soquelitinib and a strengthened balance sheet.
In atopic dermatitis, cohort 4 of the Phase 1 trial showed encouraging efficacy, with 75% of soquelitinib patients achieving EASI 75, 25% achieving EASI 90 and 33% reaching IGA 0/1, compared with 20%, 0% and 0% for placebo, alongside a clean safety profile and no dose modifications or treatment-related discontinuations across more than 14,000 treatment days. Corvus has initiated a Phase 2 atopic dermatitis trial and continues enrolling a registrational Phase 3 trial in relapsed/refractory peripheral T cell lymphoma, where soquelitinib holds Orphan Drug and Fast Track designations.
As of December 31, 2025, Corvus held $56.8 million in cash, cash equivalents and marketable securities, not including approximately $189.4 million in net proceeds from a January 23, 2026 public offering, which it expects will fund operations into the second quarter of 2028. Research and development expenses rose to $33.7 million in 2025 from $19.4 million in 2024 as clinical programs expanded, and net loss narrowed to $15.3 million from $62.3 million, partly reflecting prior-period warrant liability fair value changes.
Corvus Pharmaceuticals, Inc. insider ownership is detailed in an amended Schedule 13G filing. As of December 31, 2025, Dr. Richard A. Miller is reported as the beneficial owner of 6,085,922 shares of common stock, or 7.8% of the class, based on 74,681,872 shares outstanding as of November 4, 2025.
Dr. Miller’s position includes 1,136,707 shares held directly, 1,188,103 shares held through the Miller-Horning Family Trust, and 3,761,112 shares underlying stock options that are vested or vest within 60 days of December 31, 2025. The Miller-Horning Family Trust and Dr. Sandra J. Horning each beneficially own 1,188,103 shares, representing 1.6% of the common stock.
Adams Street investment funds updated their ownership disclosure in Corvus Pharmaceuticals after a major stock offering. Adams Street Partners and affiliated funds now beneficially own 3,275,616 shares of Corvus common stock, representing 3.9% of the 83,767,650 shares outstanding as of January 23, 2026.
The change in percentage is reported as arising solely from Corvus’ underwritten public offering, in which the company sold 7,900,677 shares at $22.15 per share and an additional 1,185,101 shares through the underwriters’ option. The Adams Street reporting group states it has not traded Corvus shares in the past 60 days.
Corvus Pharmaceuticals director and 10% owner Peter A. Thompson reported multiple option exercises linked to OrbiMed-affiliated entities. On 01/28/2026, stock options covering 210,000 shares of common stock were exercised at strike prices ranging from $0.965 to $15, resulting in 210,000 shares of common stock reported as directly owned.
An additional 8,609,091 shares of common stock are reported as indirectly owned through OrbiMed Private Investments V, LP and related OrbiMed entities. The filing states that Thompson, OrbiMed Advisors and OrbiMed Capital GP V LLC each disclaim beneficial ownership of these securities except to the extent of any pecuniary interest.
The Vanguard Group reported a passive ownership stake in Corvus Pharmaceuticals common stock. Vanguard disclosed beneficial ownership of 3,873,482 shares, representing 5.18% of the class as of December 31, 2025. Vanguard has shared voting power over 472,993 shares and shared dispositive power over all 3,873,482 shares, with no sole voting or dispositive power.
The shares are held for Vanguard’s investment clients, who are entitled to dividends and sale proceeds, and no single client holds more than 5% of the class. Vanguard also notes an internal realignment effective January 12, 2026, after which certain subsidiaries are expected to report beneficial ownership on a disaggregated basis.